From Research at med.fsu.edu Wed Jul 20 08:21:07 2022 From: Research at med.fsu.edu (med-Research) Date: Wed, 20 Jul 2022 12:21:07 +0000 Subject: Funding Opportunities Message-ID: Connect with NSF BIO: Virtual Office Hours Each division hosts regular office hours on topics of relevance to the community that provide investigators the opportunity to communicate with and ask questions of program officers. Notices are posted on NSF.gov, and more information is available on each division's blog. * Division of Biological Infrastructure: Third Tuesday of each month, 3:00-4:00 p.m. BDI supports development and enhancement of resources for research, human capital, and mid-to-large-scale infrastructure and centers to promote advances in all areas of biological research. * Division of Environmental Biology - Second Monday of each month, 1:00-2:00 p.m. DEB supports fundamental evolutionary and ecological research on species, populations, communities and ecosystems, across all spatial and temporal scales. * Division of Integrative Organismal Systems - Third Thursday of each month, 1:00-2:00 p.m. IOS supports fundamental research aimed at understanding organisms as units of biological organization, encouraging the use of integrative, interdisciplinary approaches to solving complex problems in organismal biology. * Division of Molecular and Cellular Biosciences - Second Wednesday of each month, 2:00-3:00 p.m. MCB supports quantitative and interdisciplinary approaches to deciphering the molecular underpinnings of complex living systems. Chan Zuckerberg Initiative: Insights from Single-cell Biology Datasets The Chan Zuckerberg Initiative invites applications for projects focused on advancing tools and resources that make it possible to gain greater insights into health and disease from single-cell biology datasets. This funding opportunity is specifically intended to motivate and incentivize the development, refinement, and implementation of tools and approaches that allow greater insights to be gained from available single-cell data. Any form of data generation is considered out of scope. Projects must propose and rely on open and freely available data (count matrices at minimum) at the time of application via the inclusion of a link to specific datasets in the applications. Furthermore, applications to utilize data generated outside of their labs to enable interoperability and advances that are extensible to a wider segment of interested researchers are strongly encouraged. This opportunity aims to create a network of projects that address broad computational challenges and needs within single-cell biology at a variety of scales. If applicants wish to highlight existing or prospective collaboration among projects, that is encouraged and allowable, but all applications will be reviewed for their merit and impact. Applications for two types of grants are welcome and will be reviewed independently. The maximum budgets for proposed projects are $400,000 total costs for expanded projects and $200,000 total costs for focused projects. All projects' awards will be for an 18-month duration. Successful proposals are likely to incorporate some, or multiple, of the following attributes: a meta-analysis of single-cell datasets that highlights their characteristics, usability, and utility and enables insight into more specific biological questions; develop scalable and robust tools and methods for data analysis problems in spatial transcriptomics; increase the robustness and performance of tools of broad interest for various tasks, such as data integration, scaling to higher dimensionalities, or mapping new data sets to a reference atlas that allow deeper insights; develop benchmarking frameworks, tasks, and infrastructure that enable comparisons among a class of tools and methods to stimulate future development that increases scale, efficiency, and reproducibility and accelerates scientific discovery; and improve existing tools, standards, and/or increase interoperability among multiple tools. Due August 25, 2022. Med-RA deadline to receive draft documents: August 11. Elsa U. Pardee Foundation Cancer Research Grants The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one-year period which will allow the establishment of capabilities of new cancer researchers or new cancer approaches by established cancer researchers. It is anticipated that this early-stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonable and clearly supported by the scope of the project outlined in the application. Applications requesting more than 5% overhead are usually not considered. Papers verifying nonprofit status and relevant human subject and experimental animal treatment approvals from the recipient institution will be requested prior to project initiation. A final report summarizing financial expenditure and research achievement is required. Due August 31, 2022; December 15, 2022; and April 30, 2023. Med-RA deadline to receive draft documents for August 31, 2022 due date: August 18. NSF: Division of Molecular and Cellular Biosciences: Investigator-initiated research projects (MCB) The Division of Molecular and Cellular Biosciences (MCB) supports quantitative, mechanistic, predictive, and theory-driven fundamental research designed to promote understanding of complex living systems at the molecular, subcellular, and cellular levels. While recognizing the need for thorough and accurate descriptions of biological complexes and pathways, the priority of the Division is to support work that advances the field by capturing the predictive power of mechanistic, quantitative, and evolutionary approaches. Proposals are solicited to support research relevant to the four MCB core clusters: * Cellular Dynamics and Function * Genetic Mechanisms * Molecular Biophysics * Systems and Synthetic Biology MCB gives high priority to research projects that use theory, methods, and technologies from life and physical sciences, mathematics, computational sciences, and engineering to address major biological questions that elucidate the rules governing subcellular and cellular processes. Research supported by MCB uses a range of experimental and computational approaches-including in vivo, in vitro and in silico strategies-and a broad spectrum of model and non-model organisms, including microbes and plants. Typical research supported by MCB integrates theory and experimentation. Projects are particularly welcome that address the emerging areas of: multi-scale integration; transformative methods and resources (when driven by compelling biological questions); molecular and cellular evolution; the synthesis of life-like systems; and the quantitative prediction of the phenome from genomic information. Highest funding priority is given to applications that have outstanding intellectual merit and strong broader impacts, while proposals with weaknesses in either category (or those that are perceived as likely to have an incremental impact) will not be competitive. Proposals that are motivated by relevance to human health and disease treatment are not appropriate for the Division and will be returned without review. Proposals accepted any time. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to develop and implement an environmental public health action plan based on research findings. Projects supported under this program will employ community-engaged research methods to conduct research and to translate research findings into public health action. This announcement reflects NIEHS' and NIMHD's commitment to environmental health disparities and environmental justice research. This FOA also advances efforts to nurture and sustain trust and bi-directional communication between academic researchers and affected communities. The Research to Action program is part of the National Institute of Environmental Health Sciences (NIEHS) "Partnerships for Environmental Public Health" (PEPH) network (https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm). Standard dates apply. First date: October 5, 2022. Expires September 8, 2025. Med-RA deadline to receive draft documents for October 5, 2022 standard date: September 22. NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative correlative studies in cancer patients with age, gender, racial/ethnic, or health disparities are encouraged to explore mechanisms underlying their differential responses (efficacy and toxicity) and resistance to therapeutic interventions. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). Due October 10, 2022; February 13, 2023; June 12, 2023; October 10, 2023; February 13, 2024; June 12, 2024; October 10, 2024; February 13, 2025; and June 12, 2025. Med-RA deadline to receive draft documents for October 10, 2022 due date: September 27. NHLBI Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP). Due October 11, 2022; February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024; February 11, 2025; and June 11, 2025. Med-RA deadline to receive draft documents for October 11, 2022 due date: September 28. BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. The feasibility should be established by the end of its first phase and serve as a foundation for the transition to its second phase. Fully developing the technology into a functional prototype and validating it by in-vivo animal or human function/connectivity imaging are anticipated in the second phase. The research plan should provide a realistic timeline and tangible milestones to support the proposed development effort. Awards will be integrated into the BRAIN Non-Invasive Imaging Consortium, as a coordinated network on brain function/connectivity imaging. Due October 15, 2022 and October 15, 2023. Med-RA deadline to receive draft documents for October 15, 2022 due date: October 4. Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This FOA is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins associated with rare disease. Due October 17, 2022; March 15, 2023; July 17, 2023; October 17, 2023; January 16, 2024; and July 15, 2024. Med-RA deadline to receive draft documents for October 17, 2022 due date: October 4. Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (R01 Clinical Trial Not Allowed) The purpose of this funding opportunity announcement (FOA) is to continue to support studies that characterize the structure of protein aggregates found in the Alzheimer's disease related dementias (ADRD) such as alpha-synuclein, Tau, TDP-43, TMEM106B, and FUS at a high, atomic-level resolution, using approaches such as cryo-electron microscopy (cryo-EM), cryo-electron tomogragraphy (cryo-ET), and nuclear magnetic resonance (NMR) spectroscopy. Studies in response to this FOA can also include the development of research tools and resources to further characterize and validate the structural findings and their relevance to human disease. The long-term goal of this funding opportunity is for these structural studies to inform PET ligand design for these protein aggregate species and other related applications. Due October 27, 2022. Med-RA deadline to receive draft documents: October 14. NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed) The NIDDK Central Repository houses valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at the Repository's website. Applicants must include a volume and impact assessment report from the NIDDK Central Repository with the X01 Application to document sample availability. Due October 27, 2022; March 2, 2023; June 29, 2023; October 26, 2023; March 1, 2024; June 27, 2024; October 29, 2024; March 4, 2025; and June 26, 2025. Med-RA deadline to receive draft documents for October 27, 2022 due date: October 14. Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations (R24 Clinical Trials Not Allowed) This Funding Opportunity Announcement (FOA) invites qualified academic or research institutions to apply for funding support to purchase advanced equipment that will enhance and modernize research-supporting operations of biomedical research facilities. Targeted are laboratory research core facilities, animal research facilities, and other similar shared-use research spaces. The goal of this FOA is to strengthen research-auxiliary activities of biomedical research facilities and to enhance the efficiency of their operations. This FOA does not support the purchase of scientific research instruments or their components, nor components of building-level infrastructure equipment that indirectly support research activities. Due November 7, 2022. Med-RA deadline to receive draft documents: October 25. Epigenetic Mechanisms Regulating HIV CNS Latency and Neuropathogenesis Using Novel Single Cell Technologies R01 Clinical Trial Not Allowed R21 Clinical Trial Not Allowed The purpose of these Funding Opportunity Announcements is to support studies on the epigenetic mechanisms regulating HIV Central Nervous System (CNS) latency and/or neuropathogenesis using in-vitro (macrophages, microglia and astrocytes, organoids), ex-vivo (post-mortem tissues) and in-vivo systems (animal models). Strategies to target epigenetic pathways for achieving sustained HIV remission and treatment of HIV associated-CNS dysfunction are encouraged. The use novel single cell technologies are also strongly encouraged but is not a requirement. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborations are encouraged but not required. Due December 5, 2022. Med-RA deadline to receive draft documents: November 16 (due to Thanksgiving holiday). NSF Biological Anthropology The Biological Anthropology Program supports basic research in areas related to human evolution and contemporary human biological variation. Research areas supported by the program include, but are not limited to, human genetic variation, human and nonhuman primate ecology and adaptability, human osteology and bone biology, human and nonhuman primate paleontology, functional anatomy, and primate socioecology. Grants supported in these areas are united by an underlying evolutionary framework, and often by a consideration of adaptation as a central theoretical theme. Proposals may also have a biocultural or bioarchaeological orientation. The program frequently serves as a bridge within NSF between the social and behavioral sciences and the natural and physical sciences, and proposals commonly are jointly reviewed and funded with other programs. Due January 20, 2023. Med-RA deadline to receive draft documents: January 6 (due to Martin Luther King Jr. holiday). HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional) Through the HEAL Initiative, NIH requests applications for studies designed to develop and test sustainable, scalable interventions to prevent opioid misuse, opioid use disorder, and co-occurring mental health conditions by intervening directly on social determinants of health (SDOH). This initiative aims to build an evidence base for preventive interventions that address inequities, social risks and/or social disadvantage. Interventions targeting social determinants may be structural (e.g. policy, regulatory, or systemic-wide changes) or designed to alter outcomes of individuals affected by contextual risk factors, and may be implemented in conjunction with psychosocial interventions designed to address behavioral risks. Due February 2, 2023. Med-RA deadline to receive draft documents: January 20, 2023. -------------- next part -------------- An HTML attachment was scrubbed... URL: